tradingkey.logo

GeneDx Holdings Corp

WGS
View Detailed Chart

117.210USD

+4.250+3.76%
Close 09/26, 16:00ETQuotes delayed by 15 min
3.36BMarket Cap
2393.22P/E TTM

GeneDx Holdings Corp

117.210

+4.250+3.76%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.76%

5 Days

-9.56%

1 Month

-9.27%

6 Months

+24.24%

Year to Date

+52.50%

1 Year

+173.92%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-26

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
28 / 72
Overall Ranking
152 / 4714
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
123.750
Target Price
+5.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.15% year-on-year.
Overvalued
The company’s latest PE is 1421.24, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 34.23M shares, increasing 2.89% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.18M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.10.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Ticker Symbol
Company
CEO
Website
KeyAI